Year None202120202019201820172016 September 23, 2021 Medicenna Appoints Dr. John H. Sampson to its Board of Directors Go to September 22, 2021 Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit Go to September 20, 2021 Medicenna Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program Go to September 14, 2021 Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study Go to September 9, 2021 Medicenna Therapeutics to Present at Upcoming September Investor Conferences Go to August 13, 2021 Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights Go to Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
September 20, 2021 Medicenna Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program Go to
August 13, 2021 Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights Go to
